Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UCSF
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

Official Title

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy

Keywords

Non-obstructive Hypertrophic Cardiomyopathy Cardiomyopathies Cardiomyopathy, Hypertrophic Hypertrophy IMB-1018972 IMB-1018972 200mg

Eligibility

You can join if…

Open to people ages 18-75

  • Diagnosis of Hypertrophic Cardiomyopathy consistent with current US and European guidelines
  • Ability to perform an upright treadmill cardiopulmonary exercise test
  • Agreement to abide by contraceptive requirements

You CAN'T join if...

  • Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability
  • Women who are pregnant, planning to become pregnant or lactating
  • Participation in another clinical study involving a test product or invasive medical device within 28 days (or within 5 elimination half-lives of the respective test product, whichever is longer), prior to first dosing

Locations

  • Imbria Investigational Site not yet accepting patients
    San Francisco California 94143 United States
  • Imbria Investigational Site not yet accepting patients
    Portland Oregon 97239 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Imbria Pharmaceuticals, Inc.
ID
NCT04826185
Phase
Phase 2
Study Type
Interventional
Last Updated